SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals

dc.contributor.authorRichardson, Simone I.
dc.contributor.authorMadzorera, Tatenda
dc.contributor.authorSpencer, Holly
dc.contributor.authorManamela, Nelia P.
dc.contributor.authorVan der Mescht, Mieke Adri
dc.contributor.authorLambson, Bronwen E.
dc.contributor.authorOosthuysen, Brent
dc.contributor.authorAyres, Frances
dc.contributor.authorMakhado, Zanele
dc.contributor.authorMoyo-Gwete, Thandeka
dc.contributor.authorMzindle, Nonkululeko
dc.contributor.authorMotlou, Thopisang
dc.contributor.authorStrydom, Amy
dc.contributor.authorMendes, Adriano
dc.contributor.authorTegally, Houriiyah
dc.contributor.authorDe Beer, Zelda
dc.contributor.authorDe Villiers, Talita Roma
dc.contributor.authorBodenstein, Annie
dc.contributor.authorVan den Berg, Gretha
dc.contributor.authorVenter, Marietjie
dc.contributor.authorDe Oliviera, Tulio
dc.contributor.authorUeckermann, Veronica
dc.contributor.authorRossouw, Theresa M.
dc.contributor.authorBoswell, M.T.
dc.contributor.authorMoore, Penny L.
dc.date.accessioned2023-05-10T12:20:54Z
dc.date.available2023-05-10T12:20:54Z
dc.date.issued2022-03-24
dc.description.abstractThe SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses to other variants of concern (VOCs) remains unknown. We used plasma from 20 unvaccinated and 7 vaccinated individuals infected by Omicron BA.1 to test binding, Fc effector function, and neutralization against VOCs. In unvaccinated individuals, Fc effector function and binding antibodies targeted Omicron and other VOCs at comparable levels. However, Omicron BA.1- triggered neutralization was not extensively cross-reactive for VOCs (14- to 31-fold titer reduction), and we observed 4-fold decreased titers against Omicron BA.2. In contrast, vaccination followed by breakthrough Omicron infection associated with improved cross-neutralization of VOCs with titers exceeding 1:2,100. This has important implications for the vulnerability of unvaccinated Omicron-infected individuals to reinfection by circulating and emerging VOCs. Although Omicron-based immunogens might be adequate boosters, they are unlikely to be superior to existing vaccines for priming in SARS-CoV-2-naive individuals.en_US
dc.description.departmentImmunologyen_US
dc.description.departmentMedical Virologyen_US
dc.description.librarianam2023en_US
dc.description.sponsorshipThe South African Research Chairs Initiative of the Department of Science and Innovation, the National Research Foundation of South Africa, the South African Medical Research Council Strategic Health Innovation Partnerships (SHIP) program, the Centre for the AIDS Programme of Research in South Africa (CAPRISA), the Bill and Melinda Gates Foundation through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) program and L’Oreal/UNESCO Women in Science South Africa Young Talents award.en_US
dc.description.urihttp://www.cell.com/cell-host-microbe/homeen_US
dc.identifier.citationRichardson, S.I., Madzorera, V.S., Spencer, H. et al. 2022, 'SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals', Cell Host and Microbe, vol. 30, no. 6, pp. 880-886.en_US
dc.identifier.issn1931-3128 (print)
dc.identifier.issn1934-6069 (online)
dc.identifier.other10.1016/j.chom.2022.03.029
dc.identifier.urihttp://hdl.handle.net/2263/90616
dc.language.isoenen_US
dc.publisherCell Pressen_US
dc.rights© 2022 The Authors. This is an open access article under the CC BY license.en_US
dc.subjectOmicron varianten_US
dc.subjectVaccinesen_US
dc.subjectInfectionen_US
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_US
dc.subjectVariants of concern (VOCs)en_US
dc.titleSARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individualsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
Richardson_SARSCoV2_2022.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Richardson_SARSCoV2AddFile1_2022.pdf
Size:
477.96 KB
Format:
Adobe Portable Document Format
Description:
Additional File 1
Loading...
Thumbnail Image
Name:
Richardson_SARSCoV2AddFile2_2022.pdf
Size:
1.77 MB
Format:
Adobe Portable Document Format
Description:
Additional File 2

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: